Nanoemulsions: Preparation, Stability and Application in Biosciences

Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering

Volumn , Issue , 2013, Pages 1-58

  Delmas, Thomas ^a   Atrux Tallau, Nicolas ^a,d   Goutayer, Mathieu ^a   Han, Sang Hoon ^b   Kim, Jin Woong ^c   Bibette, Jérôme ^d  

^a Capsum   (France)

^b AmorePacific Corporation   (South Korea)

^c Hanyang University   (South Korea)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

Active encapsulation; Active targeting; Entropic stabilization; Lipid nanoparticles; Nanoemulsion; Passive targeting; Release kinetics; Trapped species

Indexed keywords

EID: 84887162146     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118644591.ch1     Document Type: Chapter

References (124)

1. Y. Liu, H. Miyoshi, and M. Nakamura. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. International Journal of Cancer, 2007,120: p. 2527-2537.
2. D. Peer, et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2(12): p. 751-760.
3. L. Zhang, et al. Nanoparticles in medicine: Therapeutic applications and developments. Clinical Pharmacology and Therapeutics, 2008,83(5): p. 761-768.
4. V.P. Torchilin. Introduction. Nanocarriers for Drug Delivery: Needs and Requirements in Nanoparticulates as Drug Carriers. V.P. Torchilin, Editor 2006, Imperial College Press: London, p. 724.
5. M.L. Chen. Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective. Advanced Drug Delivery Reviews, 2008, 60(6): p. 768-777.
6. S. Chakraborty, et al. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73(1): p. 1-15.
7. M.D. Joshi, and R.H. Miiller. Lipid nanoparticles for parenteral delivery of actives. European Joural of Pharmaceutics and Biopharmaceutics, 2009, 71: p. 161-172.
8. W. Mehnert, and K. Mader. Solid lipid nanoparticles-Production, characterization and applications. Advanced Drug Delivery Reviews, 2001,47(2-3): p. 165-196.
9. R.H. Miiller, K. Mader, and S.H. Gohla. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. European Joural of Pharmaceutics and Biopharmaceutics, 2000, 50: p. 161-177.
10. T. Delmas. Encapsulation and release behavior from lipid nanoparticles: Model study with the Nile Red fluorophore. Journal of Colloid Science Bionanotechnology, 2011, In Press.
11. A.D. Bangham, and R.W. Home. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of Molecular Biology, 1964, 8: p. 660-668.
12. B. Mangenheim, M.Y. Lvy, and S. Benita. A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. International Journal of Pharmaceutics, 1993, 94: p. 115-123.
13. H. Bunjes, M.H.J. Koch, and K. Westesen. Effect of particle size on colloidal solid triglycerides. Langmuir, 2000,16(12): p. 5234-5241.
14. C. Freitas, and R.H. Miiller. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. European Joural of Pharmaceutics and Biopharmaceutics, 1999, 47(2): p. 125-132.
15. H. Bunjes, K. Westesen, and M.J.H. Koch. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. International Journal of Pharmaceutics, 1996,129(1-2): p. 159-173.
16. R.H. Miiller, M. Radtke, and S.A. Wissing. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews, 2002, 54 Supplement 1: p. 131-155.
17. A. Saupe, et al. Solid lipid nanoparticles (SLN) and Nanostructured lipid carriers (NLC)-two different carrier systems. Bio-Medical Materials and Engineering, 2005,15: p. 393-402.
18. V. Jenning, A.F. Thunemann, and S.H. Gohla. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. International Journal of Pharmaceutics, 2000,199: p. 167-177.
19. H. Bunjes, and T. Unruh. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Advanced Drug Delivery Reviews, 2007,59(6): p. 379-402.
20. K. Westesen, and H. Bunjes. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? International Journal of Pharmaceutics, 1995,115(1): p. 129-131.
21. M. Garcia-Fuentes, M.J. Alonso, and D. Torres. Design and characterization of a new drug nanocarrier made from solid-liquid mixtures. Journal of Colloid and Interface Science, 2005,285: p. 590-598.
22. K. Jores, et al. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and raman spectroscopy. Pharmaceutical Research, 2005,22(11): p. 1887-1897.
23. K. Jores, et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. Journal of Controlled Release, 2004,95: p. 217-227.
24. K. Jores, W. Mehnert, and K. Mader. Physicochemical investigations on solid lipid nanoparticles and oil-loaded solid lipid nanoparticles: A nuclear magnetic resonance and electron spin resonance study. Pharmaceutical Research, 2003,20(8): p. 1274-1283.
25. J. Bibette, F.L. Calderon, and P. Poulin. Emulsions: Basic principles. Reports on Progress in Physics, 1999, 62(6): p. 969-1033.
26. F. Leal-Calderon, V. Schimtt, and J. Bibette. Emulsions Science: Basic Principles, 2nd ed. Springer Tracks in Modern Physics, Vol. 181. 2007: Springer, p. 228.
27. I. Capek. Degradation of kinetically-stable o/w emulsions. Advances in Colloid and Interface Science, 2004,107(2-3): p. 125-155.
28. B. Cabane, and S. Henon. Liquides: Solutions, Dispersions, Emulsions, Gels. Belin ed. Collection Echelles, 2003: Belin.
29. T. Tadros, et al. Formation and stability of nanoemulsions. Advances in Colloid and Interface Science, 2004,108-109: p. 303-318.
30. T.G. Mason, et al. Nanoemulsions: Formation, structure, and physical properties, journal of Physics-Condensed Matter, 2007, 19(7): p. 079001.
31. O. Sonneville-Aubrun, et al. Phase transition pathways for the production of 100 nm oil-in-water emulsions. Physical Chemistry Chemical Physics, 2009,11(1): p. 101-110.
32. L. Taisne, and B. Cabane. Emulsification and ripening following a temperature quench. Langmuir, 1998,14(17): p. 4744-4752.
33. K. Shinoda, and S. Friberg. Microemulsions: Colloidal aspects. Advances in Colloid and Interface Science, 1975,4: p. 281-300.
34. I. Danielsson, and B. Lindman. The definition of microemulsion. Colloids and Surfaces, 1981, 3: p. 391-392.
35. C. Solans, et al. Nano-emulsions. Current Opinion in Colloid and Interface Science, 2005,10: p. 102-105.
36. T. Delmas, et al. How to produce and stabilize very small nanoemulsions. Langmuir, 2011, 27(5): p. 1683-1692.
37. G.I. Taylor. The formation of emulsions in definable fields of flow. Proceedings of the Royal Society, 1934, A146: p. 501.
38. T.S.H. Leong, et al. Minimising oil droplet size using ultrasonic emulsification. Ultrasonics Sonochemistry, 2009,16(6): p. 721-727.
39. U. El-Jaby, M. Cunningham, and T.E. McKenna. Comparison of emulsification devices for the production of miniemulsions. Industrial and Engineering Chemistry Research, 2009,48: p. 10147-10151.
40. B. Abismail, et al. Emulsification by ultrasound: Drop size distribution and stability. Ultrasonics Chemistry, 1999, 6: p. 75-83.
41. K. Shinoda, and H. Saito. The effect of temperature on the phase equilibria and the types of dispersion of the ternary system composed of water, cyclohexane and nonionic surfactant. Journal of Colloid and Interface Science, 1968,26: p. 70-74.
42. U. Olsson, K. Shinoda, and B. Lindman. Change of structure of microemulsions with the hydrophile-Lipophile balance of non ionic surfactant as revealed by NMR self-diffusion studies. Journal of Physical Chemistry, 1986, 90: p. 4083-4086.
43. P. Izquierdo, et al. The influence of surfactant mixing ratio on nanoemulsion formation by the pit method. Journal of Colloid and Interface Science, 2005,285(1): p. 388-394.
44. T. Tadros, et al. Formation and Stability of Nano-emulsions. In: 3rd World Congress on Emulsion, 2002, Lyon, FRANCE: Elsevier Science Bv.
45. L. Taisne, P. Walstra, and B. Cabane. Transfer of oil between emulsion droplets. Journal of Colloid and Interface Science, 1996, 184(2): p. 378-390.
46. A. Kabalnov. Thermodynamic and theoretical aspects of emulsions and their stability. Current Opinion in Colloid & Interface Science, 1998, 3(3): p. 270-275.
47. F. Leal-Calderon, and P. Poulin. Progress in understanding emulsion metastability and surface forces. Current Opinion in Colloid & Interface Science, 1999,4(3): p. 223-230.
48. P. Poulin, and J. Bibette. Wetting of emulsions droplets: From macroscopic to colloidal scale. Physical Review Letters, 1997, 79(17): p. 3290-3292.
49. C. Wagner. Theorie der alterung von niederschlagen durch umlosen. Zeitschrift fur Elecktrochemie, 1961, 65: p. 581-594.
50. M. Lifshitz, and V.V. Slyozov. The kinetics of precipitation from supersaturated solid solutions. Journal of Physics and Chemistry of Solids, 1961,19: p. 35-50.
51. B. Deminiere, et al. "Vieillissement par coalescence et duree de vie d'une emulsion concentree," Comptes Rendus de I'Academie des Sciences Paris-Chimie Physique et Theorique, 1998, tome KSerie II c): p. 163-165.
52. K. Pays, et al. Understanding the stability and lifetime of emulsions. Journal of Dispersion Science and Technology, 2002,23(1-3): p.175-186.
53. B. Deminiere, et al. Cell growth in a 3D cellular system undergoing coalescence. Physical Review Letters, 1999, 82(1): p. 229-232.
54. T.J. Wooster, M. Golding, and P. Sanguansri. Impact of Oil Type on Nanoemulsion Formation and Ostwald Ripening Stability. Langmuir, 2008, 24(22): p. 12758-12765.
55. H. Egger, and K.M. McGrath. Aging of oil-in-water emulsions: The role of the oil. Journal of Colloid and Interface Science, 2006, 299(2): p. 890-899.
56. A.J. Webster, and M.E. Cates. Stabilization of emulsions by trapped species. Langmuir, 1998,14(8): p. 2068-2079.
57. A. Kabalnov. Ostwald ripening and related phenomena. Journal of Dispersion Science and Technology, 2001, 22(1): p. 1-12.
58. A.J. Webster, and M.E. Cates. Osmotic stabilization of concentrated emulsions and foams. Langmuir, 2001,17(3): p. 595-608.
59. O. Sonneville-Aubrun, J.T. Simonnet, and F. L'Alloret. Nanoemulsions: A new vehicle for skincare products. Advances in Colloid and Interface Science, 2004,108-109: p. 145.
60. T. Delmas, et al. Preparation and characterization of highly stable lipid nanoparticles with amorphous core of tuneable viscosity. Journal of Colloid and Interface Science, 2011, 360(2): p. 471-481.
61. J. Rossi, and J.C. Leroux, Principles in the Development of Intraveneous Lipid Emulsions, in Role of Lipids Excipients in Modifying Oral a Parenteral Drug Delivery, K.M. Wasan, Editor 2007, John Wiley & Sons, Inc.: Hoboken, New Jersey, USA.
62. G.A. Lewis, D. Mathieu, and R. Phan-Tan-Luu. "Pharmaceutical and Experimental Design," Drugs and the Pharmaceutical Sciences, Vol. 92. 1999, New York: Marcel Decker, Inc.
63. J. Goupy, La Methodologie des Plans D'experiences:Optimisation du Choix des Essais & de L'interpretation des Resultats, 1988, Paris: Dunod. 303.
64. O.C. Farokhzad, and R. Langer. Impact of Nanotechnology on Drug Delivery. ACS Nano, 2009, 3(1): p. 16-20.
65. EX. Gu, et al. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2(3): p. 14-21.
66. D.K. Kim, and J. Dobson. Nanomedicine for targeted drug delivery. Journal of Materials Chemistry, 2009,19: p. 6294-6307.
67. T. Kissel. Particulate nanomedicines. Advanced Drug Delivery Reviews, 2006, 58: p. 1451-1455.
68. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 2008, 60: p. 1615-1626.
69. E Dahnier, O. Feron, and V. Preat. To exploit the tumor microenvironnement: passive and active tumor targeting of nanocarriers for anticancer drug delivery. Journal of Controlled Release, 2010,148: p. 135-146.
70. K. Greish. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. Journal of Drug Targeting, 2007,15(7-8): p. 457-464.
71. M. Wang, and M. Thanou. Targeting nanoparticles to cancer. Pharmacological Research, 2010, 62(2): p. 90-99.
72. S.M. Moghimi, and T. Kissel. Particulate nanomedicines. Advanced Drug Delivery Reviews, 2006, 58: p. 1451-1455.
73. I. Texier, et al. Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging. Journal of Biomedical Optics, 2009, 14(5): p. 054005.
74. K. Sato. In: Crystallisation and Polymorphism of Fats and Fatty Acids, N. Garli and K. Sato, Editors. 1988, M. Dekker Inc.: New york.
75. K. Sato. Crystallization behaviour of fats and lipids-a review. Chemical Engineering Science, 2001,56(7): p. 2255-2265.
76. PR. Smith, and M.J.W. Pvey. The effect of partial glycerides on trilaurin crystallization. Journal of the American Oil Chemists Society, 1997, 74(2): p. 169-171.
77. F. Han, et al. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids and Surfaces A: Physicochemical Engineering Aspects, 2008, 315: p. 210-216.
78. T. Unruh, et al. Investigations on the melting behaviour of triglyceride nanoparticles. Colloid and Polymer Science, 2001, 279(4): p. 398-403.
79. M.A. Schubert, B.C. Schicke, and C.C. Miiller-Goymann. Thermal analysis of the crystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin. International Journal of Pharmaceutics, 2005, 298(1): p. 242-254.
80. K. Westesen, H. Bunjes, and M.J.H. Koch. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. Journal of Controlled Release, 1997,48: p. 223-236.
81. P. Taylor. Ostwald ripening in emulsions. Advances in Colloid and Interface Science, 1998, 75(2): p. 107-163.
82. B. Heurtault, et al. Physico-chemical stability of colloidal lipid particles. Biomaterials, 2003, 24: p. 4283-4300.
83. C. Schwarz, and W. Mehnert. Freeze-drying of drug-free and drugloaded solid lipid nanoparticles (SLN). International Journal of Pharmaceutics, 1997,157: p. 171-179.
84. R. Cavalli, et al. Sterilization and freeze-drying of drug-free and drugloaded solid lipid nanoparticles. International Journal of Pharmaceutics, 1997,148: p. 47-54.
85. P. Shahgaldian, et al. A study of the freeze-drying conditions of calixarene based solid lipid nanoparticles. European Joural of Pharmaceutics and Biopharmaceutics, 2003,55: p. 181-184.
86. H. Bunjes, F. Steiniger, and W. Richter. Visualizing the structure of triglycerides nanoparticles in different crystal modifications. Langmuir, 2007, 23: p. 4005-4011.
87. A. zur Mulhen, C. Schwarz, and W. Mehnert. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. European Joural of Pharmaceutics and Biopharmaceutics, 1998,45: p. 149-155.
88. M. Schwab, et al. Studies of the lipase induced degradation of lipid based drug delivery systems. Journal of Controlled Release, 2009,140: p. 27-33.
89. C. Olbrich, and R.H. Miiller. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. International Journal of Pharmaceutics, 1999,180: p. 31-39.
90. R.H. Miiller, D. Riihl, and S.A. Runge. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. International Journal of Pharmaceutics, 1996,144: p. 115-121.
91. C. Olbrich, O. Kayser, and R.H. Miiller. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles-effect of surfactant, storage time and cristallinity. International Journal of Pharmaceutics, 2002,237: p. 119-128.
92. H. Bunjes, and M.H.J. Koch. Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglycerides nanoparticles. Journal of Controlled Release, 2005,107: p. 229-243.
93. J. Gravier, et al. Lipidots: Competitive organic alternative to quantum dots for in vivo fluorescence imaging, Journal of Biomedical Optics, 16(9): p, 096013.
94. Navarro, E, et al. Preparation, characterization and cellular studies of photosensitizer-loaded lipid nanoparticles for photodynamic therapy. In: BIOS, 2011. San Francisco, California, USA.
95. N. Atrux Tallau, et al. One shot nanoemulsion production for targeting skin cells. Submitted to Journal of Colloid and Interface Science, 2012.
96. J. Merian, et al. Development and use of vectorized lipid nanoparticles (LNP) for PET and fluorescence imaging in oncology. Bulletin du Cancer, 2010, 97(SI): p. S16-S16.
97. F. Navarro. Lipid Nanoparticles vectorization of Indocyanine green improves non invasive fluorescence imaging. Submited to Molecular Imaging, 2011.
98. F.P. Navarro, et al. A novel indocyanine green nanoparticle probe for non invasive fluorescence imaging in vivo. Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications, ed. S. Achilefu and R. Raghavachari. Vol. 7190. 2009: Proceedings of SPIE.
99. L. Hu, Z. Mao, and C. Gao. Colloidal particles for cellular uptake and delivery. Journal of Materials Chemistry, 2009,19: p. 3108-3115.
100. M. Massignani, et al. Controlling cellular uptake bu surface chemistry, size and surface topology at the nanoscale. Small, 2009, 5(21): p. 2424-2432.
101. A. Dhawan, and V. Sharma. Toxicity assessment of nanomaterials: methods and challenges. Analytical and Bioanalytical Chemistry, 2010, 389: p. 589-605.
102. M.A. Dobrovolskaia, D.R. Germolec, and J.I. Weaver. Evaluation of nanoparticle immunotoxicity Nature Nanotechnology, 2009, 4: p. 411-414.
103. I. Lynch, and K.A. Dawson. Protein-nanoparticle interactions. Nano Today, 2008,3(1-2): p. 40-7.
104. T. Delmas. Caracterisation physicochimique et comprehension des proprietes de vectorisation des nanoparticules lipidiques pour les applications biomedicales. In: Physicochimie & Chimie Analytiaue 2011, Universite Pierre et Marie Curie-Paris 6, p. 320.
105. F. Mitler, et al. Lipidots: Des nanoparticules biodegradables pour l'imagerie medicale et/ou la delivrance de medicaments. In Materiaux 2010,2010: Nantes, France.
106. B. Fadeel, and A. Garcia-Bennett. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Advanced Drug Delivery Reviews, 2010, 62: p. 362-374.
107. C. Hanley, et al. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Research Letters, 2009,4: p. 1409-1420.
108. R. Muller, et al. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfacatant. Pharmaceutical Research, 1997, 14(4): p. 458-i62.
109. N. Scholer, et al. Surfactants, but not the size of solid lipid nanoparticles influences viability and cytokine production of macrophages. International Journal of Pharmaceutics, 2001, 221: p. 57-67.
110. C. Olbrich, et al. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles on RAW 264.7 macrophages-impact of phagocytosis on viability and cytokine production. Journal of Pharmacy and Pharmacology, 2004,56(7): p. 883-891.
111. R. Muller, and C. Olbrich. Solid Lipid Nanoparticles: Phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Pharmazeutische Industrie, 1999, 61(5): p. 462-467.
112. A.D. Maynard. Nanotechnology: Assessing the risks. Nano Today, 2006,1(2): p. 22-33.
113. M.A. Maurer-Jones, et al. Toxicity of therapeutic nanoparticles. Nanomedicine, 2009,4(2): p. 219-241.
114. H. Maeda, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 2000, 65: p. 271-284.
115. M. Goutayer, et al. Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo fluorescence imaging. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75: p. 137-147.
116. J. Gravier, et al. Lipidots: A competitive organic alternative to quantum dots for in vivo fluorescence imaging. Journal of Biomedical Optics, 2011,16(9).
117. B. Baroli. Penetration of nanoparticles and nanomaterials in the skin: Fiction or reality? Journal of Pharmaceutical Science, 2010, 99(1): p. 21-50.
118. V. Teeranachaideekul, et al. Influence of oil content on physicochemical properties and skin distribution of Nile Red-loaded NLC. Journal of Controlled Release, 2008,128: p. 134-141.
119. Z.A. Aziz, et al. Production of asiaticoside and madecassoside in Centella asiatica in vitro and in vivo. Biologia Plantarum, 2007, 51(1): p. 34-2.
120. R.K. Verma, et al. Reverse-phase High Performance Liquid Chromatography of Asiaticoside in Centella asiatica. Phytochemical Analysis, 1999,10: p. 191-193.
121. P. Hashim, et al. Triterpene composition and bioactivities of Centella asiatica. Molecules, 2011,16(2): p. 1310-22.
122. B. Tang, et al. Asiaticoside suppresses collagen expression and TGF-beta/Smad signaling through inducing Smad7 and inhibiting TGF-betaRI and TGF-betaRII in keloid fibroblasts. Archives of dermatological research, 2011, 303(8): p. 563-72.
123. J.H. Sampson, et al. In vitro keratinocyte antiproliferant effect of Centella asiatica extract and triterpenoid saponins. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 2001,8(3): p. 230-5.
124. N.H. Abu Samah, and CM. Heard. Topically applied KTTKS: A review. International Journal of Cosmetic Science, 2011,33(6): p. 383-390.